Gantenerumab
(Anti-human amyloid β mAb, human IgG1-Kappa; RG1450)
Catalog No.: PC-Ab1093Not For Human Use, Lab Use Only.
Gantenerumab (RG1450, RO4909832) is a fully human IgG1 antibody designed to bind with subnanomolar affinity to a conformational epitope on Aβ fibrils. It encompasses both N-terminal and central amino acids of Aβ. The therapeutic rationale for this antibody is that it acts centrally to disassemble and degrade amyloid plaques by recruiting microglia and activating phagocytosis. bind and reduce amyloid-beta plaque formation in the brain, a hallmark of Alzheimer’s. It also neutralizes oligomeric Aβ4
Gantenerumab (RG1450, RO4909832) is a fully human IgG1 antibody designed to bind with subnanomolar affinity to a conformational epitope on Aβ fibrils. It encompasses both N-terminal and central amino acids of Aβ. The therapeutic rationale for this antibody is that it acts centrally to disassemble and degrade amyloid plaques by recruiting microglia and activating phagocytosis. bind and reduce amyloid-beta plaque formation in the brain, a hallmark of Alzheimer’s. It also neutralizes oligomeric Aβ42-mediated inhibitory effects on long-term potentiation in rat brains. In APP/PS-1 transgenic mice, gantenerumab binds to cerebral Aβ, reduces small plaques by recruiting microglia, and prevents new plaque formation. Gantenerumab does not alter plasma Aβ.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
